A novel cycloalkylamine salt of 2-(1-hydroxypentyl)benzoate
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECH CO LTD
- Filing Date
- 2023-03-22
- Publication Date
- 2026-05-26
AI Technical Summary
Existing butylphthalide drugs suffer from poor water solubility, low solubility, insufficient efficacy, and difficult preparation processes when treating ischemic cardiovascular and cerebrovascular diseases, which limits their clinical application. Furthermore, there is a lack of intravenous injection drugs with high safety and significant efficacy.
A novel cycloalkanamine salt of 2-(1-hydroxypentyl)benzoic acid was developed. By reacting with an organic solvent at a specific temperature to form a salt, a compound with good solid form and significant efficacy was formed, which is suitable for the preparation of pharmaceutical compositions such as tablets, capsules, large-volume infusions, small-volume injections, or granules.
The compound achieves a good solid form, enhances its antiplatelet aggregation effect and improves neurological symptoms, and has high solubility and stability. It is suitable for the prevention and treatment of ischemic heart and brain diseases, especially mild, moderate and severe acute ischemic stroke, and has high toxicity and good safety.
Smart Images

Figure CN116262698B_ABST
Abstract
Citation Information
Patent Citations
Novel 2-(alpha-hydroxyl amyl) and its preparing method and use
CN1523003A
5-bromine-2-([alpha]-hydroxypentyl)benzoic acid sodium salts in different crystal forms, and preparation method thereof
CN105517988A
Brain damage resistance deuterated compounds and medical use thereof
CN108947946A